Overview

Study of a Single Subcutaneous Dose of Pozelimab Produced From Two Different Manufacturing Processes in Healthy Adult Participants

Status:
Completed
Trial end date:
2021-03-05
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to compare the pharmacokinetic(PK) profile of pozelimab produced by the original manufacturing process (Process A) compared to a second manufacturing process (Process B) The secondary objectives of the study are: - Assess the safety and tolerability of a single SC dose of pozelimab produced by the 2 manufacturing processes - Assess the immunogenicity of pozelimab produced by the 2 manufacturing processes
Phase:
Phase 1
Details
Lead Sponsor:
Regeneron Pharmaceuticals